139 related articles for article (PubMed ID: 11844603)
1. No thoracic radiation myelitis after spinal cord dose > or = 50.4 Gy using 1.2. Gy b.i.d. fractionation in patients with Stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy.
Jeremic B; Shibamoto Y; Milicic B; Dagovic A; Aleksandrovic J; Nikolic N; Igrutinovic I
Lung Cancer; 2002 Mar; 35(3):287-92. PubMed ID: 11844603
[TBL] [Abstract][Full Text] [Related]
2. Absence of thoracic radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for Stage III nonsmall-cell lung cancer.
Jeremic B; Shibamoto Y; Milicic B; Acimovic L; Milisavljevic S
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):343-6. PubMed ID: 9457819
[TBL] [Abstract][Full Text] [Related]
3. Absence of cervical radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for locally advanced, unresectable, nonmetastatic squamous cell carcinoma of the head and neck.
Jeremic B; Shibamoto Y; Igrutinovic I
J Cancer Res Clin Oncol; 2001 Nov; 127(11):687-91. PubMed ID: 11710599
[TBL] [Abstract][Full Text] [Related]
4. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
[TBL] [Abstract][Full Text] [Related]
5. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
Jeremić B; Milicić B
Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
[TBL] [Abstract][Full Text] [Related]
6. Stage III non-small-cell lung cancer treated with high-dose hyperfractionated radiation therapy and concurrent low-dose daily chemotherapy with or without weekend chemotherapy: retrospective analysis of 301 patients.
Jeremic B; Milicic B; Dagovic A; Aleksandrovic J; Milisavljevic S
Am J Clin Oncol; 2004 Aug; 27(4):350-60. PubMed ID: 15289727
[TBL] [Abstract][Full Text] [Related]
7. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients.
Jeremić B; Miličić B; Milisavljevic S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1157-63. PubMed ID: 21640518
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04.
Komaki R; Seiferheld W; Ettinger D; Lee JS; Movsas B; Sause W
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):548-57. PubMed ID: 12062596
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer.
Jeremic B; Shibamoto Y; Acimovic L; Djuric L
J Clin Oncol; 1995 Feb; 13(2):452-8. PubMed ID: 7844608
[TBL] [Abstract][Full Text] [Related]
10. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.
Jeremic B; Shibamoto Y; Acimovic L; Milisavljevic S
J Clin Oncol; 1996 Apr; 14(4):1065-70. PubMed ID: 8648358
[TBL] [Abstract][Full Text] [Related]
11. Interfraction interval in patients with stage III non-small-cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy: final results in 536 patients.
Jeremic B; Milicic B; Dagovic A; Aleksandrovic J; Milisavljevic S
Am J Clin Oncol; 2004 Dec; 27(6):616-25. PubMed ID: 15577441
[TBL] [Abstract][Full Text] [Related]
12. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
[TBL] [Abstract][Full Text] [Related]
13. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial.
Jeremic B; Shibamoto Y; Acimovic L; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):19-25. PubMed ID: 11316542
[TBL] [Abstract][Full Text] [Related]
14. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129
[TBL] [Abstract][Full Text] [Related]
15. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.
Pradier O; Lederer K; Hille A; Weiss E; Christiansen H; Schmidberger H; Hess CF
J Cancer Res Clin Oncol; 2005 Apr; 131(4):261-9. PubMed ID: 15616830
[TBL] [Abstract][Full Text] [Related]
16. Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer.
Jeremic B; Shibamoto Y
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):303-8. PubMed ID: 8567330
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
[TBL] [Abstract][Full Text] [Related]
19. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation.
Binkley MS; Hiniker SM; Chaudhuri A; Maxim PG; Diehn M; Loo BW; Shultz DB
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):808-15. PubMed ID: 26831903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
